ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2677

Healthcare Resources Utilization in Giant Cell Arteritis – a Population-Based Study

Aladdin Mohammad1, Aleksandra Turkiewicz 2, Pavlos Stamatis 1, Carl Turesson 3, Martin Englund 2 and Ali Kiadaliri 2, 1Lund University, Lund, Skane Lan, Sweden, 2Lund University, Lund, Sweden, 3Lund University, Malmö, Sweden

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: giant cell arteritis, Health care cost, population studies and Health Care

  • Tweet
  • Email
  • Print
Session Information

Date: Tuesday, November 12, 2019

Title: Vasculitis – Non-ANCA-Associated & Related Disorders Poster III: Giant Cell Arteritis

Session Type: Poster Session (Tuesday)

Session Time: 9:00AM-11:00AM

Background/Purpose: To study the healthcare resource utilization (HRU) in patients with giant cell arteritis (GCA) compared with the background population in southern Sweden.

Methods: The study includes patients diagnosed with biopsy-proven GCA between 2001 and 2011 and their randomly selected age-, sex- and residency area matched reference persons (1:10). Data on all healthcare consultations and admissions were extracted from a regional administrative database, the Skåne Healthcare Register, which records data on all healthcare consultations and hospitalizations using the ICD-10 codes. Frequencies of HRU were analysed as numbers and rates of primary healthcare visits, hospital visits and hospitalizations. HRU was assessed from three years prior to index date (i.e. the date of GCA diagnosis for both GCA and their respective matched reference subjects) to five years after. The HRU (i.e. the number of healthcare visits) during 5 years after the index date was analysed using zero-inflated negative binomial regressions assuming the same propensity to use healthcare for both GCA and references and adjusted for sex, age, year of diagnosis, and HRU over 3-year before index date.

Results: The matched cohort included a total of 7,282 subjects (GCA patients, n = 662; references,

n =6,620) with mean (SD) age 75.3 (8.3) years, and 73.4% women. Over 5 years after index date, HRU was higher in patients with GCA compared to reference subjects with incidence rate ratios of 1.36 (95% CI 1.29-1.44) for all visits, 1.21 (1.14-1.28) for primary healthcare physician visits and 1.47 (1.39-1.56) for specialist care physician visits (Table 1). Hospital admissions were more frequent among GCA patients with rate ratios of 1.23 (1.11-1.36) for admissions and 1.41 (1.24-1.60) for inpatient days. Notably, the HRU started to diverge from the year before the index date up to four years after (Figure 1). When stratifying consultations or hospitalization by diagnoses, consultations rates were higher in GCA patients than in reference subjects for the following diagnoses: infections, cardiovascular diseases, respiratory diseases, musculoskeletal, nervous disorders and ear and eye diseases. However, endocrine diagnoses were lower prior to the onset of GCA compared to the period preceding the index date in reference subjects. 

Conclusion: In this population-based study, patients with GCA had higher rates of HRU compared to the reference population. The increase in HRU was evident one year before diagnosis and continued over four years after. The systemic inflammatory burden and the adverse effects of treatment may account for the increase in the HRU after GCA diagnosis.


Table 1_HRU_ACR2019

Table 1. Incidence rate ratio -95% confidence interval- of different study outcomes -healthcare visits and admission to hospitals- for GCA patients vs. reference subjects.


Fig1

Figure 1. The mean numbers of visits to different level of healthcare providers three years before and five years after date of diagnosis of giant cell arteritis -GCA- or index date for reference subjects.


Disclosure: A. Mohammad, None; A. Turkiewicz, None; P. Stamatis, None; C. Turesson, None; M. Englund, None; A. Kiadaliri, None.

To cite this abstract in AMA style:

Mohammad A, Turkiewicz A, Stamatis P, Turesson C, Englund M, Kiadaliri A. Healthcare Resources Utilization in Giant Cell Arteritis – a Population-Based Study [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/healthcare-resources-utilization-in-giant-cell-arteritis-a-population-based-study/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/healthcare-resources-utilization-in-giant-cell-arteritis-a-population-based-study/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology